相扑蛋白
脱氮酶
癌症研究
雷达51
DNA损伤
同源重组
生物
DNA修复
癌变
泛素
奥沙利铂
调节器
EZH2型
泛素连接酶
肿瘤进展
染色质
下调和上调
化学
DNA损伤修复
组蛋白
癌症
邻近连接试验
化疗
作者
Jie Gao,Nan Bai,M. LIU,Ninghua Yao,Zhangzhi Tang,Bin Xu,W. Chen,Xuyang He,Jiayu Shao,Saiyan Bian,Hui Zhao,Wenjie Zheng
出处
期刊:Oncogenesis
[Springer Nature]
日期:2025-12-22
卷期号:14 (1): 49-49
标识
DOI:10.1038/s41389-025-00592-z
摘要
Although the FOLFOX strategy has demonstrated benefits for tumor patients at advanced stages, chemoresistance remains a significant challenge to therapeutic efficacy. Thus, identifying strategies to overcome chemoresistance and enhance chemotherapy sensitivity is critical for optimizing HAIC-FOLFOX treatment. Comprehensive investigations of deubiquitinating enzymes (DUBs) across multiple bioinformatics cohorts and a local hepatocellular carcinoma (HCC) cohort identified ubiquitin-specific protease 1 (USP1) as a key regulator of HCC progression, correlating with poor survival outcomes. Functional assays demonstrated that USP1 overexpression promotes aggressive phenotypes in HCC cells, including enhanced proliferation, migration, and epithelial-mesenchymal transition (EMT), whereas USP1 inhibitor ML323 suppresses these effects and increases sensitivity to oxaliplatin and fluorouracil (5-FU), the primary agents in FOLFOX, both in vitro and in vivo. Mechanistic studies revealed that USP1 interacted with and stabilized the chromatin-remodeling factor lymphoid-specific helicase (HELLS) through deubiquitinating, thereby facilitating EMT and homologous recombination repair (HRR), thereby driving chemoresistance. Furthermore, USP1 promoted HELLS SUMOylation by stabilizing PIAS1, an E3 SUMO ligase, through deubiquitination and prevention of its ubiquitin-mediated degradation. Importantly, inhibition of SUMOylation significantly attenuated the aggressive effects mediated by USP1. In conclusion, this study highlights the USP1/PIAS1/HELLS deubiquitinating and SUMOylation axis as a critical driver of aggressiveness and DNA damage repair responses in HCC cells, offering a promising therapeutic strategy to suppress HCC progression and enhance the efficacy of FOLFOX-based chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI